Why India is moving beyond generics
Patented medicines, biologics and precision therapies increasingly drive the global pharmaceutical market. As India works towards a USD 400-450 billion pharmaceutical industry by 2047, sustained growth will depend on creating greater value through research, innovation and intellectual property alongside manufacturing excellence.
The shift is already underway.
Indian pharmaceutical companies are increasing investments in research and development, with more than 40 New Chemical Entities (NCEs) and New Biological Entities (NBEs) under development. This momentum is supported by growing investments in biologics, biosimilars and complex therapies, the rapid expansion of India's CRDMO sector, and government initiatives that are strengthening the research and innovation ecosystem.
Recent achievements illustrate this progress. Glenmark's first-in-class trispecific antibody ISB 2001 for multiple myeloma represents one of India's most promising oncology innovations. Wockhardt's novel antibiotic Zaynich, developed to treat drug-resistant bacterial infections, addresses one of the world's most urgent public health priorities. Zydus Lifesciences' ZyCoV-D, the world's first plasmid DNA COVID-19 vaccine approved for human use, demonstrated India's ability to develop an indigenous vaccine from discovery through commercialisation.
The growing number of global licensing, out-licensing and co-development partnerships signals that multinational companies increasingly view Indian firms as innovation partners rather than manufacturing partners alone.
India’s opportunity: Affordable innovation
India's next opportunity is not simply to develop innovative medicines, but to make innovation more affordable and accessible to patients anywhere.
Affordable Innovation is the ability to combine scientific excellence, efficient research, scalable manufacturing and cost-effective development to bring breakthrough therapies within reach of more patients. This is where India's long-standing strengths in scientific capability, regulated quality, manufacturing scale and affordability create a distinctive global advantage.
These strengths create an opportunity not simply to discover new medicines, but to make innovation more accessible worldwide.
Building an enabling innovation ecosystem
Pharmaceutical innovation remains one of the most complex and high-risk scientific endeavours. Drug development often takes more than a decade, requires substantial investment and carries a high rate of attrition.
Sustaining the innovation momentum will require continued progress in five areas: modern regulatory pathways for emerging therapies; long-term incentives for research and development; robust digital and health data infrastructure; greater participation in global clinical research; and stronger collaboration between industry, academia and research institutions.
Government initiatives, including the National Biopharma Mission, the Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme and Biopharma SHAKTI, are helping strengthen capabilities across the innovation value chain—from discovery and clinical development to manufacturing and commercialisation.
India's next pharmaceutical transformation
India's leadership in generic medicines transformed access to treatment for millions of patients worldwide. The next opportunity is to apply the same philosophy to innovative medicines.
India's next pharmaceutical transformation will not replace its identity as the Pharmacy of the World; it will build on it. Success will be measured not only by the medicines India manufactures, but by the innovative therapies it discovers, develops and delivers affordably to patients worldwide. That is what will define India's emergence as the Global Champion of Affordable Innovation.
